Anemia Associated with Impaired Erythropoietin Secretion after Allogeneic Stem Cell Transplantation: Incidence, Risk Factors, and Response to Treatment

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 8, 2008, Pages 880-887

  Gaya, Anna ^a   Urbano Ispizua, Alvaro ^a   Fernández Avilés, Francesc ^a   Salamero, Olga ^a   Roncero, Josep María ^a   Rovira, Montserrat ^a   Martínez, Carmen ^a   Talarn, Carme ^a   Granell, Miquel ^a   Carreras, Enric ^a   Montserrat, Emili ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Allogeneic stem cell transplantation; Anemia; Erythropoietin; Renal dysfunction

Indexed keywords

CREATININE; EPOPEN; ERYTHROPOIETIN; FERRITIN; FOSCARNET; GANCICLOVIR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; VALGANCICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; INCIDENCE; IRON OVERLOAD; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROTEIN BLOOD LEVEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; ANEMIA; ERYTHROPOIESIS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 48949118512     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.05.008     Document Type: Article

References (56)

1. Miller C.B., Jones R.J., Zahurak M.L., et al. Impaired erythropoietin response to anemia after bone-marrow transplantation. Blood 80 (1992) 2677-2682
2. Altes A., Remacha A.F., Sureda A., et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 29 (2002) 987-989
3. Altes A., Remacha A.F., Sarda P., et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 34 (2004) 505-509
4. Llewelyn C.A., Hewitt P.E., Knight R.S.G., et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363 (2004) 417-421
5. Peden A.H., Head M.W., Ritchie D.L., et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364 (2004) 527-529
6. Beguin Y., Clemons G.K., Oris R., and Fillet G. Circulating erythropoietin levels after bone-marrow transplantation-inappropriate response to anemia in allogeneic transplants. Blood 77 (1991) 868-873
7. Bosi A., Vannucchi A.M., Grossi A., et al. Serum erythropoietin levels in patients undergoing autologous bone-marrow transplantation. Bone Marrow Transplant 7 (1991) 421-425
8. Schapira L., Antin J.H., Ransil B.J., et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76 (1990) 2354-2359
9. Beguin Y., Oris R., and Fillet G. Dynamics of erythropoietic recovery following bone-marrow transplantation-role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 11 (1993) 285-292
10. Ireland R.M., Atkinson K., Concannon A., et al. Serum erythropoietin changes in autologous and allogeneic bone-marrow transplant patients. Br J Haematol 76 (1990) 128-134
11. Schuster S.J., Wilson J.H., Erslev A.J., and Caro J. Physiological regulation and tissue localization of renal erythropoietin messenger-RNA. Blood 70 (1987) 316-318
12. Koury S.T., Bondurant M.C., and Koury M.J. Localization of erythropoietin synthesizing cells in murine kidneys by insitu hybridization. Blood 71 (1988) 524-527
13. Lacombe C., Dasilva J.L., Bruneval P., et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81 (1988) 620-623
14. Koury S.T., Koury M.J., Bondurant M.C., et al. Quantitation of erythropoietin-producing cells in kidneys of mice by insitu hybridization-correlation with hematocrit, renal erythropoietin messenger-RNA, and serum erythropoietin concentration. Blood 74 (1989) 645-651
15. Vannucchi A.M., Grossi A., Bosi A., et al. Impaired erythropoietin production in mice treated with cyclosporine-A. Blood 78 (1991) 1615-1618
16. Klaesson S., Ringden O., Ljungman P., et al. Reduced blood-transfusions requirements after allogeneic bone-marrow transplantation-results of a randomized, double-blind-study with high-dose erythropoietin. Bone Marrow Transplant 13 (1994) 397-402
17. Steegmann J.L., Lopez J., Otero M.J., et al. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution-results of a prospective controlled randomized trial. Bone Marrow Transplant 10 (1992) 541-546
18. Link H., Boogaerts M.A., Fauser A.A., et al. A controlled trial of recombinant-human-erythropoietin after bone-marrow transplantation. Blood 84 (1994) 3327-3335
19. Baron F., Sautois B., Baudoux E., et al. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation. Exp Hematol 30 (2002) 546-554
20. Biggs J.C., Atkinson K.A., Booker V., et al. Prospective randomized double-blind trial of the in-vivo use of recombinant-human-erythropoietin in bone-marrow transplantation from HLA-identical sibling donors. Bone Marrow Transplant 15 (1995) 129-134
21. Fox C.P., Pacey S., Das-Gupta E.P., et al. Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT. Transfusion Med 15 (2005) 475-480
22. Urbano-Ispizua A., Brunet S., Solano C., et al. Allogeneic transplantation of CD34(+)-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplantat 28 (2001) 349-354
23. Cazzola M. Erythropoietin pathophysiology and erythropoietin deficiency anemia. Hematol J 5 (2004) S100-S103
24. Kamble R.T., Selby G.B., Mims M., et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12 (2006) 506-510
25. Porter J.B. Practical management of iron overload. Br J Haematol 115 (2001) 239-252
26. Katodritou E., Zervas K., Terpos E., and Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol (2008)
27. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor-alpha precede major complications of bone-marrow transplantation. Blood 75 (1990) 1011-1016
28. Cazzola M., Mercuriali F., and Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 89 (1997) 4248-4267
29. Cazzola M., Ponchio L., deBenedetti F., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 87 (1996) 4824-4830
30. Roodman G.D., Bird A., Hutzler D., and Montgomery W. Tumor-necrosis-factor-alpha and hematopoietic progenitors-effects of tumor-necrosis-factor on the growth of erythroid progenitors CFU-e and BFU-e and the hematopoietic-cell lines K562, Hl60, and Hel cells. Exp Hematol 15 (1987) 928-935
31. Schooley J.C., Kullgren B., and Allison A.C. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anemias. Br J Haematol 67 (1987) 11-17
32. Parikh C.R., McSweeney P.A., Korular D., et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 62 (2002) 566-573
33. Bennett W.M. The nephrotoxicity of immunosuppressive drugs. Clin Nephrol 43 (1995) S3-S7
34. Bennett W.M., DeMattos A., Meyer M.M., et al. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 50 (1996) 1089-1100
35. Remuzzi G., and Perico N. Cyclosporine-induced renal dysfunction in experimental-animals and humans. Kidney Int 48 (1995) S70-S74
36. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 311 (1984) 699-705
37. Oriji G.K., and Keiser H.R. Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension 32 (1998) 849-855
38. Abdelrahman M., Sharples E.J., McDonald M.C., et al. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22 (2004) 63-69
39. Sharples E.J., Patel N., Brown P., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15 (2004) 2115-2124
40. Bahlmann F.H., Song R., Boehm S.M., et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. J Hypertens 22 (2004) S283
41. Patel N.S.A., Sharples E.J., Cuzzocrea S., et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int 66 (2004) 983-989
42. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40 (2004) 2201-2216
43. Bokemeyer C., Aapro M.S., Courdi A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43 (2007) 258-270
44. Baron F., Fillet G., and Beguin Y. Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation 74 (2002) 1692-1696
45. Angelucci E., Muretto P., Nicolucci A., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100 (2002) 17-21
46. Carmine T.C., Evans P., Bruchelt G., et al. Presence of iron catalytic for free-radical reactions in patients undergoing chemotherapy-implications for therapeutic management. Cancer Lett 94 (1995) 219-226
47. Halliwell B., Gutteridge J.M.C., and Cross C.E. Free-radicals, antioxidants, and human-disease-where are we now. J Lab Clin Med 119 (1992) 598-620
48. Lucarelli G., Galimberti M., Polchi P., et al. Bone-marrow transplantation in patients with thalassemia. N Engl J Med 322 (1990) 417-421
49. de la Serna J., Bornstein R., Garcia-Bueno M.J., and Lahuerta-Palacios J.J. Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity. Bone Marrow Transplant 23 (1999) 95-97
50. Beutler E., Hoffbrand A.V., and Cook J.D. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program (2003) 40-61
51. Bullen J.J. The significance of iron in infection. Rev Infect Dis 3 (1981) 1127-1138
52. Iglesias-Osma C., Gonzalez-Villaron L., San Miguel J.F., et al. Iron metabolism and fungal infections in patients with haematological malignancies. J Clin Pathol 48 (1995) 223-225
53. Beutler E., Felitti V., Ho N.J., and Gelbart T. Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol 107 (2002) 145-149
54. Kooistra M.P., Vanes A., Struyvenberg A., and Marx J.J.M. Iron-metabolism in patients with the anemia of end-stage renal-disease during treatment with recombinant-human-erythropoietin. Br J Haematol 79 (1991) 634-639
55. Brugnara C., Chambers L.A., Malynn E., et al. Red-blood-cell regeneration induced by subcutaneous recombinant erythropoietin-iron-deficient erythropoiesis in iron-replete subjects. Blood 81 (1993) 956-964
56. Major A., Bauer C., Breymann C., et al. Rh-erythropoietin stimulates immature reticulocyte release in man. Br J Haematol 87 (1994) 605-608